Open Access<p>Analysis of the Doxorubicin and Doxorubicinol in the Plasma of Breast Cancer Patients for Monitoring the Toxicity of Doxorubicin</p>
Author(s) -
Yahdiana Harahap,
Puspitasari Ardiningsih,
Agatha Corintias Winarti,
Denni Joko Purwanto
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s251144
Subject(s) - doxorubicin , anthracycline , chemistry , cardiotoxicity , pharmacology , medicine , chromatography , breast cancer , cancer , toxicity , chemotherapy
Doxorubicin is an anthracycline antibiotic used as an anticancer agent. Long-term use of this anticancer agent could accumulate its metabolite, doxorubicinol, and cause cardiomyopathy, due to its cardiotoxicity. This cardiotoxic effect depends on the amount of doxorubicin and doxorubicinol accumulated in the body. This study aimed to analyze doxorubicin and doxorubicinol levels in the blood plasma of breast cancer patients.